-
Je něco špatně v tomto záznamu ?
A comprehensive analysis of germline predisposition to early-onset ovarian cancer
K. Horackova, P. Zemankova, P. Nehasil, M. Vocka, M. Hovhannisyan, K. Matejkova, M. Janatova, M. Cerna, P. Kleiblova, S. Jelinkova, B. Stastna, P. Just, T. Dolezalova, B. Nemcova, M. Urbanova, M. Koudova, J. Hazova, E. Machackova, L. Foretova, V....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
Grantová podpora
NU20-03-00016
Ministerstvo Zdravotnictví Ceské Republiky
NU20-03-00016
Ministerstvo Zdravotnictví Ceské Republiky
NU20-03-00016
Ministerstvo Zdravotnictví Ceské Republiky
NU20-03-00016
Ministerstvo Zdravotnictví Ceské Republiky
NU20-09-00355
Ministerstvo Zdravotnictví Ceské Republiky
RVO-VFN 00064165
Ministerstvo Zdravotnictví Ceské Republiky
NU20-09-00355
Ministerstvo Zdravotnictví Ceské Republiky
RVO-VFN 00064165
Ministerstvo Zdravotnictví Ceské Republiky
RVO-VFN 00064165
Ministerstvo Zdravotnictví Ceské Republiky
RVO-VFN 00064165
Ministerstvo Zdravotnictví Ceské Republiky
RVO-VFN 00064165
Ministerstvo Zdravotnictví Ceské Republiky
RVO-VFN 00064165
Ministerstvo Zdravotnictví Ceské Republiky
RVO-VFN 00064165
Ministerstvo Zdravotnictví Ceské Republiky
NU20-03-00016
Ministerstvo Zdravotnictví Ceské Republiky
NU20-03-00016
Ministerstvo Zdravotnictví Ceské Republiky
NU20-03-00016
Ministerstvo Zdravotnictví Ceské Republiky
NU20-03-00016
Ministerstvo Zdravotnictví Ceské Republiky
COOPERATIO
Univerzita Karlova v Praze
COOPERATIO
Univerzita Karlova v Praze
COOPERATIO
Univerzita Karlova v Praze
COOPERATIO
Univerzita Karlova v Praze
COOPERATIO
Univerzita Karlova v Praze
COOPERATIO
Univerzita Karlova v Praze
COOPERATIO
Univerzita Karlova v Praze
COOPERATIO
Univerzita Karlova v Praze
COOPERATIO
Univerzita Karlova v Praze
SVV260631
Univerzita Karlova v Praze
COOPERATIO
Univerzita Karlova v Praze
COOPERATIO
Univerzita Karlova v Praze
COOPERATIO
Univerzita Karlova v Praze
COOPERATIO
Univerzita Karlova v Praze
COOPERATIO
Univerzita Karlova v Praze
COOPERATIO
Univerzita Karlova v Praze
LX22NPO05102
Ministerstvo Školství, Mládeže a Tělovýchovy
LX22NPO05102
Ministerstvo Školství, Mládeže a Tělovýchovy
LX22NPO05102
Ministerstvo Školství, Mládeže a Tělovýchovy
LX22NPO05102
Ministerstvo Školství, Mládeže a Tělovýchovy
LX22NPO05102
Ministerstvo Školství, Mládeže a Tělovýchovy
LX22NPO05102
Ministerstvo Školství, Mládeže a Tělovýchovy
LX22NPO05102
Ministerstvo Školství, Mládeže a Tělovýchovy
LX22NPO05102
Ministerstvo Školství, Mládeže a Tělovýchovy
LX22NPO05102
Ministerstvo Školství, Mládeže a Tělovýchovy
LX22NPO05102
Ministerstvo Školství, Mládeže a Tělovýchovy
The National Center for Medical Genomics (LM2023067)
Ministerstvo Školství, Mládeže a Tělovýchovy
LX22NPO05102
Ministerstvo Školství, Mládeže a Tělovýchovy
LX22NPO05102
Ministerstvo Školství, Mládeže a Tělovýchovy
NLK
Directory of Open Access Journals
od 2011
Free Medical Journals
od 2011
Nature Open Access
od 2011-12-01
PubMed Central
od 2011
Europe PubMed Central
od 2011
ProQuest Central
od 2011-01-01
Open Access Digital Library
od 2011-01-01
Open Access Digital Library
od 2011-01-01
Health & Medicine (ProQuest)
od 2011-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2011
Springer Nature OA/Free Journals
od 2011-12-01
- MeSH
- checkpoint kinasa 2 genetika MeSH
- dospělí MeSH
- genetická predispozice k nemoci * MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- nádory vaječníků * genetika MeSH
- studie případů a kontrol MeSH
- věk při počátku nemoci * MeSH
- zárodečné mutace * MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
The subset of ovarian cancer (OC) diagnosed ≤ 30yo represents a distinct subgroup exhibiting disparities from late-onset OC in many aspects, including indefinite germline cancer predisposition. We performed DNA/RNA-WES with HLA-typing, PRS assessment and survival analysis in 123 early-onset OC-patients compared to histology/stage-matched late-onset and unselected OC-patients, and population-matched controls. Only 6/123(4.9%) early-onset OC-patients carried a germline pathogenic variant (GPV) in high-penetrance OC-predisposition genes. Nevertheless, our comprehensive germline analysis of early-onset OC-patients revealed two divergent trajectories of potential germline susceptibility. Firstly, overrepresentation analysis highlighted a connection to breast cancer (BC) that was supported by the CHEK2 GPV enrichment in early-onset OC(p = 1.2 × 10-4), and the presumably BC-specific PRS313, which successfully stratified early-onset OC-patients from controls(p = 0.03). The second avenue pointed towards the impaired immune response, indicated by LY75-CD302 GPV(p = 8.3 × 10-4) and diminished HLA diversity compared with controls(p = 3 × 10-7). Furthermore, we found a significantly higher overall GPV burden in early-onset OC-patients compared to controls(p = 3.8 × 10-4). The genetic predisposition to early-onset OC appears to be a heterogeneous and complex process that goes beyond the traditional Mendelian monogenic understanding of hereditary cancer predisposition, with a significant role of the immune system. We speculate that rather a cumulative overall GPV burden than specific GPV may potentially increase OC risk, concomitantly with reduced HLA diversity.
Centre for Medical Genetics and Reproductive Medicine GENNET Prague Czech Republic
Department of Biochemistry Faculty of Science Charles University Prague Czech Republic
Department of Cancer Epidemiology and Genetics Masaryk Memorial Cancer Institute Brno Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24019748
- 003
- CZ-PrNML
- 005
- 20250515095927.0
- 007
- ta
- 008
- 241015s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41598-024-66324-2 $2 doi
- 035 __
- $a (PubMed)39003285
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Horackova, Klara $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 245 12
- $a A comprehensive analysis of germline predisposition to early-onset ovarian cancer / $c K. Horackova, P. Zemankova, P. Nehasil, M. Vocka, M. Hovhannisyan, K. Matejkova, M. Janatova, M. Cerna, P. Kleiblova, S. Jelinkova, B. Stastna, P. Just, T. Dolezalova, B. Nemcova, M. Urbanova, M. Koudova, J. Hazova, E. Machackova, L. Foretova, V. Stranecky, M. Zikan, Z. Kleibl, J. Soukupova
- 520 9_
- $a The subset of ovarian cancer (OC) diagnosed ≤ 30yo represents a distinct subgroup exhibiting disparities from late-onset OC in many aspects, including indefinite germline cancer predisposition. We performed DNA/RNA-WES with HLA-typing, PRS assessment and survival analysis in 123 early-onset OC-patients compared to histology/stage-matched late-onset and unselected OC-patients, and population-matched controls. Only 6/123(4.9%) early-onset OC-patients carried a germline pathogenic variant (GPV) in high-penetrance OC-predisposition genes. Nevertheless, our comprehensive germline analysis of early-onset OC-patients revealed two divergent trajectories of potential germline susceptibility. Firstly, overrepresentation analysis highlighted a connection to breast cancer (BC) that was supported by the CHEK2 GPV enrichment in early-onset OC(p = 1.2 × 10-4), and the presumably BC-specific PRS313, which successfully stratified early-onset OC-patients from controls(p = 0.03). The second avenue pointed towards the impaired immune response, indicated by LY75-CD302 GPV(p = 8.3 × 10-4) and diminished HLA diversity compared with controls(p = 3 × 10-7). Furthermore, we found a significantly higher overall GPV burden in early-onset OC-patients compared to controls(p = 3.8 × 10-4). The genetic predisposition to early-onset OC appears to be a heterogeneous and complex process that goes beyond the traditional Mendelian monogenic understanding of hereditary cancer predisposition, with a significant role of the immune system. We speculate that rather a cumulative overall GPV burden than specific GPV may potentially increase OC risk, concomitantly with reduced HLA diversity.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a genetická predispozice k nemoci $7 D020022
- 650 12
- $a zárodečné mutace $7 D018095
- 650 12
- $a nádory vaječníků $x genetika $7 D010051
- 650 12
- $a věk při počátku nemoci $7 D017668
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a studie případů a kontrol $7 D016022
- 650 _2
- $a mladý dospělý $7 D055815
- 650 _2
- $a checkpoint kinasa 2 $x genetika $7 D064447
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Zemankova, Petra $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Nehasil, Petr $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Vocka, Michal $u Department of Oncology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Hovhannisyan, Milena $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Matějková, Kateřina, $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic $u Department of Genetics and Microbiology, Faculty of Science, Charles University in Prague, Prague, Czech Republic $d 1998- $7 xx0332267
- 700 1_
- $a Janatova, Marketa $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Cerna, Marta $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Kleiblova, Petra $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Jelinkova, Sandra $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Stastna, Barbora $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic $u Department of Biochemistry, Faculty of Science, Charles University, Prague, Czech Republic
- 700 1_
- $a Just, Pavel $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Dolezalova, Tatana $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Nemcova, Barbora $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Urbanova, Marketa $u Centre for Medical Genetics and Reproductive Medicine, GENNET, Prague, Czech Republic
- 700 1_
- $a Koudova, Monika $u Centre for Medical Genetics and Reproductive Medicine, GENNET, Prague, Czech Republic
- 700 1_
- $a Hazova, Jana $u Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic
- 700 1_
- $a Machackova, Eva $u Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic
- 700 1_
- $a Foretova, Lenka $u Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic
- 700 1_
- $a Stranecky, Viktor $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Zikan, Michal $u Department of Gynecology and Obstetrics, Bulovka University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Kleibl, Zdenek $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Soukupova, Jana $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic. jana.soukupova@lf1.cuni.cz
- 773 0_
- $w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 14, č. 1 (2024), s. 16183
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39003285 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241015 $b ABA008
- 991 __
- $a 20250515095927 $b ABA008
- 999 __
- $a ok $b bmc $g 2202149 $s 1231721
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 14 $c 1 $d 16183 $e 20240713 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
- GRA __
- $a NU20-03-00016 $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a NU20-03-00016 $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a NU20-03-00016 $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a NU20-03-00016 $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a NU20-09-00355 $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a RVO-VFN 00064165 $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a NU20-09-00355 $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a RVO-VFN 00064165 $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a RVO-VFN 00064165 $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a RVO-VFN 00064165 $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a RVO-VFN 00064165 $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a RVO-VFN 00064165 $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a RVO-VFN 00064165 $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a NU20-03-00016 $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a NU20-03-00016 $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a NU20-03-00016 $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a NU20-03-00016 $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a COOPERATIO $p Univerzita Karlova v Praze
- GRA __
- $a COOPERATIO $p Univerzita Karlova v Praze
- GRA __
- $a COOPERATIO $p Univerzita Karlova v Praze
- GRA __
- $a COOPERATIO $p Univerzita Karlova v Praze
- GRA __
- $a COOPERATIO $p Univerzita Karlova v Praze
- GRA __
- $a COOPERATIO $p Univerzita Karlova v Praze
- GRA __
- $a COOPERATIO $p Univerzita Karlova v Praze
- GRA __
- $a COOPERATIO $p Univerzita Karlova v Praze
- GRA __
- $a COOPERATIO $p Univerzita Karlova v Praze
- GRA __
- $a SVV260631 $p Univerzita Karlova v Praze
- GRA __
- $a COOPERATIO $p Univerzita Karlova v Praze
- GRA __
- $a COOPERATIO $p Univerzita Karlova v Praze
- GRA __
- $a COOPERATIO $p Univerzita Karlova v Praze
- GRA __
- $a COOPERATIO $p Univerzita Karlova v Praze
- GRA __
- $a COOPERATIO $p Univerzita Karlova v Praze
- GRA __
- $a COOPERATIO $p Univerzita Karlova v Praze
- GRA __
- $a LX22NPO05102 $p Ministerstvo Školství, Mládeže a Tělovýchovy
- GRA __
- $a LX22NPO05102 $p Ministerstvo Školství, Mládeže a Tělovýchovy
- GRA __
- $a LX22NPO05102 $p Ministerstvo Školství, Mládeže a Tělovýchovy
- GRA __
- $a LX22NPO05102 $p Ministerstvo Školství, Mládeže a Tělovýchovy
- GRA __
- $a LX22NPO05102 $p Ministerstvo Školství, Mládeže a Tělovýchovy
- GRA __
- $a LX22NPO05102 $p Ministerstvo Školství, Mládeže a Tělovýchovy
- GRA __
- $a LX22NPO05102 $p Ministerstvo Školství, Mládeže a Tělovýchovy
- GRA __
- $a LX22NPO05102 $p Ministerstvo Školství, Mládeže a Tělovýchovy
- GRA __
- $a LX22NPO05102 $p Ministerstvo Školství, Mládeže a Tělovýchovy
- GRA __
- $a LX22NPO05102 $p Ministerstvo Školství, Mládeže a Tělovýchovy
- GRA __
- $a The National Center for Medical Genomics (LM2023067) $p Ministerstvo Školství, Mládeže a Tělovýchovy
- GRA __
- $a LX22NPO05102 $p Ministerstvo Školství, Mládeže a Tělovýchovy
- GRA __
- $a LX22NPO05102 $p Ministerstvo Školství, Mládeže a Tělovýchovy
- LZP __
- $a Pubmed-20241015